Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 5/20 | 0.44 |
| ▸ | MPO | P05164 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CCNC | P24863 | 1/20 | 0.40 |
| ▸ | CDK8 | P49336 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | VNN1 | O95497 | 1/20 | 0.39 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.39 |
| ▸ | TCF7 | P36402 | 1/20 | 0.39 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.39 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
| ▸ | CTSC | P53634 | 1/20 | 0.36 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16406907 | 0.89 | CTNNB1 (0.50) | CACNA1HMPOCCNCCDK8VNN1 | |
| SCHEMBL8172855 | 0.79 | MPO (0.47) | CACNA1HMPOCYP1A2CCNCCDK8 | |
| SCHEMBL29426964 | 0.77 | MPO (0.46) | CACNA1HMPOCYP1A2CCNCCDK8 | |
| SCHEMBL29585470 | 0.77 | MPO (0.49) | CACNA1HMPOCCNCCDK8NOTUM | |
| SCHEMBL30903411 | 0.77 | NOTUM (0.52) | CACNA1HMPOCCNCCDK8NOTUM | |
| SCHEMBL24339179 | 0.77 | MPO (0.46) | CACNA1HMPOCYP1A2CCNCCDK8 | |
| SCHEMBL904805 | 0.77 | MPO (0.49) | CACNA1HMPOCCNCCDK8NOTUM | |
| SCHEMBL14800197 | 0.77 | NOTUM (0.52) | CACNA1HMPOCCNCCDK8NOTUM | |
| SCHEMBL7431709 | 0.76 | CACNA1H (0.48) | CACNA1HNOTUMERCC1ERCC4IRAK4 | |
| SCHEMBL13548299 | 0.76 | CTNNB1 (0.47) | CACNA1HMPOCYP1A2CCNCCDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-06 | — | — | US | disclosed |
| US-12459920-B2 | Targeted protein degradation | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-04 | — | — | US | disclosed |
| US-20250243180-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-07-31 | — | — | US | disclosed |
| WO-2025024521-A1 | SUBSTITUTED PIPERIDINEDIONES FOR TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS, INC. (US) | 2025-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250243180-A1 | TARGETED PROTEIN DEGRADATION | NEK7, NEK1, RIPK1 | CACNA1H 4209/4885MPO 1433/4885CYP1A2 4493/4885 |
| US-12459920-B2 | Targeted protein degradation | NEK7, NEK1, RIPK1 | CACNA1H 4215/4885MPO 1434/4885CYP1A2 4503/4885 |
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | NEK7, NEK1, RIPK1 | CACNA1H 4209/4885MPO 1433/4885CYP1A2 4493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.